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Inﬂ uenza subjects with an antiviral claim within one day pre- and one day post-index 
and/or an antibiotic claim within three days pre- and three days post-index were 
identiﬁ ed. Subjects with a secondary respiratory infection within the two week post-
index period were identiﬁ ed via ICD-9 codes. RESULTS: The study cohort included 
270,057 members with inﬂ uenza (51.8% male; mean age 31.6 years). Antibiotics were 
prescribed in 63,358 (23.5%) of subjects (42,374 [15.7%] received an antibiotic only; 
20,984 [7.8%] received both an antiviral and an antibiotic). The majority of subjects 
with inﬂ uenza (157,447 [58.3%]) did not receive an antiviral. Among subjects receiv-
ing antibiotic treatment, 98.9% did not have a follow-up coded respiratory bacterial 
infection within two weeks. The mean antibiotic costs were $66.15 and $42.71 for 
subjects with and without a secondary bacterial respiratory infection, respectively. 
Antibiotic usage in inﬂ uenza subjects without a secondary bacterial respiratory infec-
tion accounted for approximately $2.7M (2009 US$). CONCLUSIONS: Almost all 
subjects with inﬂ uenza receiving antibiotic treatment did not have a secondary bacte-
rial respiratory condition. The cost associated with the empiric prescribing of antibiot-
ics was considerable. Furthermore, over half the subjects with inﬂ uenza did not receive 
antiviral therapy. As our study only allowed for one case per subject the total cost 
associated with empiric antibiotic prescribing in subjects with inﬂ uenza is likely an 
underestimate.
PIN22
A NOVEL APPROACH FOR ESTIMATING THE VALUE OF ENTECAVIR 
THERAPY FOR NUCLEOSIDE-NAÏVE CHRONIC HEPATITIS B PATIENTS 
IN SPAIN
Ramirez de Arellano A1, Fernandez-Rodriguez C2, Andrade R3, Clemente G4, Sola R5, 
Wells J6, Rentero P1
1Bristol-Myers Squibb Iberia, Madrid, Spain; 2Hospital Fundación Alcorcón, Madrid, Spain; 
3Hospital Virgen de la Victoria, Malaga, Spain; 4General Hospital Gregorio Marañon, Madrid, 
Spain; 5Hospital del Mar (IMIM), Barcelona, Spain; 6Monitor Group, London, UK
OBJECTIVES: Prescribers, payers and health care decision-makers operating in 
diverse health care settings are increasingly examining the value of innovative treat-
ments. The analysis aims at estimating the relative value of the two preferred ﬁ rst-line 
oral antiviral treatment options for chronic hepatitis B (CHB) according to the EASL 
guidelines: entecavir (ETV) and tenofovir (TDF) from a Spanish payer’s perspective. 
METHODS: Hepatitis B disease was simulated using a health-state transition model 
with disease-states deﬁ ned as mild disease (Ishak F0/F1), ﬁ brosis (F2–F4) and advanced 
ﬁ brosis/cirrhosis (>F4), and complicated disease-states (decompensated cirrhosis, 
hepatocellular carcinoma, liver transplant and death) based on available natural 
history data. The value of treatment-speciﬁ c attributes on disease progression/regres-
sion was estimated from clinical practice data in real world settings in terms of lifetime 
events and costs avoided. Treatment attributes included: additional testing require-
ments at treatment initiation and required renal function monitoring; adverse events 
per product labelling; reversal of ﬁ brosis; and treatment intensiﬁ cation in case of 
suboptimal viral suppression to avoid potential resistance. a 5-year treatment duration 
was assumed. Primary model output is the estimated cost avoided per-patient per day 
of treatment, associated with the clinical attributes of ETV compared to TDF in the 
treatment of nucleoside-naïve HBeAg-positive and -negative CHB patients. RESULTS: 
The daily cost of antiviral therapy for a CHB patient was estimated at c13.2 for ETV 
compared to c9.6 with TDF. Lifetime treatment cost avoided due to ETV’s clinical 
attributes was quantiﬁ ed at c3.6 [95% conﬁ dence: interval: 2, 5.2] per day of therapy. 
CONCLUSIONS: Estimating total treatment cost-avoidance associated with speciﬁ c 
clinical attributes is a novel approach in assessing the value of treatment options. ETV 
exhibits the characteristics of a favourable CHB treatment option, which directly 
translates into economic and therapeutic added value.
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BACKGROUND: Visceral leishmaniasis (VL) (“Kalazar”) is an important public 
health issue in Brazil. The guidelines of Brazilian Ministry of Health set up pentavalent 
antimony as the ﬁ rst line treatment, and amphotericin (deoxicolate and liposomal) as 
the second line treatment of VL. There are evidences that liposomal amphotericin (LA) 
and amphotericin deoxicolate (AD) present similiar efﬁ cacy, but LA has a better safety 
proﬁ le. Unfortunately, its price has been the principal barrier to its usage by public 
health system. OBJECTIVES: To evaluate the impact of differential pricing policy of 
LA in the Brazilian public health system. METHODS: The global amount spent on 
medicines from 2007 to 2009 by the Ministry of Health on the different types of 
treatment was retrieved from the Brazilian sanitary surveillance system. The following 
associated costs were also analyzed: hospital care and professional services; laborato-
rial tests (potassium, urea, creatinine and transaminases); and loss of working days 
(average daily income). This information allowed us to perform the cost analysis of 
the different therapeutic options. RESULTS: The differential pricing policy for LA 
implemented in 2008 allowed a cost reduction of 76.8% (from US$5.881 to US$590 
per treatment) enabling the Ministry of Health to double the number of patients 
treated with LA. The associated costs of hospitalization and loss of productivity by 
patients are higher with AD than with LA, but the total cost of LA treatment (medica-
tion + associated costs) is still 11.3% to 27% higher. CONCLUSIONS: In a societal 
perspective it was shown that a substantial price reduction of a safer drug enhanced 
its use and distribution by the Ministry of Health. It became also evident that the 
policy of differential pricing is an effective way to promote access to an efﬁ cient and 
safer treatment of VL, a disease that mainly affects the poor.
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OBJECTIVES: The primary aim of this study was to determine the possible impact 
of appropriate prescribing of antibiotics on treatment outcomes, days of patient 
hospitalization and costs related to antibiotic treatment. METHODS: Data from case 
notes of all inpatients on antibiotic treatment and all antibiotic prescriptions from 
outpatient departments were collected from June 15 to July 15, 2006 at 5 government 
and mission hospitals in Lesotho. All prescriptions were classiﬁ ed into categories of 
appropriateness based on their conformities to criteria developed from principles of 
antibiotic prescribing. Analyses were further conducted to determine the possible 
impact that appropriate prescribing may have on treatment outcomes, days of patient 
hospitalization and costs of antibiotic treatments. RESULTS: A total of 307 inpatients 
and 867 outpatient prescriptions were assessed. Total frequencies of prescribed anti-
biotics were 584 and 1073 for inpatients and outpatients respectively. For inpatients 
antibiotics were most often prescribed for skin and soft tissue (31.7%) and respiratory 
tract (28.9%) infections. Outpatients received most antibiotics for respiratory tract 
(42.0%) and skin and soft tissue infection (21.9%) respectively. Of the 307 inpatient 
prescriptions 41.6% were appropriately written for either empiric treatment or pro-
phylaxis of infections while 57.1% did not conform to antibiotic prescribing princi-
ples. a majority (81.0%) of outpatient prescriptions were in line with the prescribing 
principles. Inpatient antibiotic prescribing patterns based on principles of antibiotic 
prescribing have had a positive impact on treatment outcomes, days of hospitalization 
and costs of antibiotic treatment. In outpatients prescribing of antibiotics based on 
principles of antibiotic prescribing failed to show any signiﬁ cant impact on costs of 
antibiotics. Due to geographical challenges the outcome for treatment could not be 
determined for outpatients. CONCLUSIONS: Rational prescribing had a positive 
impact on treatment outcomes.
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OBJECTIVES: To assess cost-beneﬁ t and cost-effectiveness studies examining seasonal 
inﬂ uenza vaccination in the healthy, working-age population of the United States (US). 
METHODS: A systematic review of economic evaluations investigating the cost-
beneﬁ t or cost-effectiveness of vaccinating healthy adults was conducted on articles 
published between January 1990 and January 2010. Studies considered for inclusion 
in this review were identiﬁ ed using Medline, Embase, Econlit, and Google Scholar (n 
= 11). The source and appropriateness of parameters (epidemiological data, probabili-
ties, and costs), the designs employed, and the sufﬁ ciency of sensitivity analysis were 
considered during the review. RESULTS: Seven studies were identiﬁ ed as appropriate 
for this review. Key inputs of the selected studies included inﬂ uenza or ILI attack rates, 
outpatient visits averted, total vaccination costs, and lost workdays. All studies were 
conducted in the US and from the societal perspective; three were randomized, clinical 
trials and the remaining four constructed economic simulation models to compare 
vaccination to antivirals or no intervention. Results ranged from net savings of $69.19 
to net costs of $85.89 per vaccination (4 studies) and from $103.95 to $1004.85 per 
episode of inﬂ uenza averted (1 study). Only 2 studies reported cost-effectiveness ratios; 
these ranged from $6,930 to $50,510 per quality-adjusted life-year gained. Nearly all 
of the studies conducted sensitivity analysis; results were most sensitive to variation 
in wage rates, levels of worker productivity, the cost and effectiveness of vaccination, 
and the rate of illness. CONCLUSIONS: This systematic review found that seasonal 
inﬂ uenza vaccination of healthy, working-age adults is generally not cost saving, 
requiring an investment to generate health beneﬁ ts. The decision to vaccinate such a 
group will depend upon the societal and payer valuation of those beneﬁ ts.
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OBJECTIVES: Identifying budgetary implications and opportunities for earlier detec-
tion versus late detection of HIV (CD4 cell count less than 200/μl) in the 1 through 
5 year term following diagnosis. In 2009, there were 90,468 HIV positive individuals 
not accounting for unreported HIV positive cases (in 2008, estimated additional 24%). 
Late detection HIV patients account for 32% from the total. METHODS: A literature 
review was conducted using MEDLINE, Cochrane Library, EMBASE and CRD for 
guidelines and clinical trials published 1995–2010 in UK, England, Scotland, Wales, 
Northern Ireland, USA, Canada, Australia, Norway and EU-26. We extrapolated UK 
